(Q44982796)

8 December 2017

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure (English)

1 reference

8 December 2017

0 references

1

Eva Poveda

1 reference

8 December 2017

10

Vincent Soriano

1 reference

8 December 2017

8

François Clavel

1 reference

8 December 2017

2

Berta Rodés

1 reference

8 December 2017

6

Juan González-Lahoz

1 reference

8 December 2017

7

Jean-Louis Faudon

1 reference

8 December 2017

Jean-Louis Labernardière

3

1 reference

8 December 2017

José Miguel Benito

4

1 reference

8 December 2017

Carlos Toro

5

1 reference

8 December 2017

Jonathan Schapiro

9

1 reference

8 December 2017

1 September 2004

1 reference

Journal of Medical Virology

8 December 2017

1 reference

8 December 2017

74

1 reference

8 December 2017

1

1 reference

8 December 2017

21-28

1 reference

Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.

8 December 2017

1 reference

CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy

21 January 2018

1 reference

Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120

21 January 2018

1 reference

Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain

21 January 2018

1 reference

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

21 January 2018

1 reference

Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans

21 January 2018

1 reference

Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage

21 January 2018

1 reference

Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors

21 January 2018

1 reference

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.

21 January 2018

1 reference

Immune activation and induction of HIV-1 replication within CD14 macrophages during acute Plasmodium falciparum malaria coinfection.

21 January 2018

1 reference

Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor

21 January 2018

1 reference

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

21 January 2018

1 reference

Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes

21 January 2018

1 reference

Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia.

21 January 2018

1 reference

21 January 2018

1 reference

Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control

21 January 2018

1 reference

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JMV.20141

1 reference

8 December 2017

1 reference